News Releases

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 29, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV),   today announced the acceptance of multiple abstracts at the 2024 Bradykinin Symposium taking place in Berlin, Germany   September 5-6, 2024 .

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 15, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the European Medicines Agency (EMA) has validated the submission of a Marketing Authorization Application (MAA) for sebetralstat, a novel, investigational

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted eleven newly-hired employees inducement options to purchase an aggregate of 90,000 shares

– Submitted NDA for sebetralstat as first-ever, oral on-demand treatment for HAE attacks, a pivotal moment for the HAE community – – Potential FDA approval and launch of sebetralstat in first half 2025 - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 84,000 shares

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 27, 2024-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 18, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein

– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable and non-prescription

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 4, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of

– Patient perspectives reveal the challenges of injecting on-demand therapies and the consequences of delayed or withheld treatment - – Physicians characterize breakthrough HAE attacks occurring in patients receiving non-androgen long-term prophylaxis - CAMBRIDGE, Mass.